ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. Most-Favored Nation (MFN) International reference pricing. Make America Healthy Again (MAHA) Commission. Proposed regulations. Global Benchmark for Efficient Drug Pricing (GLOBE) Model.
2026 · 3rd Quarter (July 1 - Sep 30)
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS
Filed by AEGIS LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 17, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- AEGIS LLC
- Filing UUID
- 96b23de6-bc56-4204-9d14-d367bb093195
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.